Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data Immunome Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
14
9.04
6.94
Research and development
8.82
7.49
14.1
23.3
23.1
130
177
General and administrative
1.53
4.78
11.1
13.6
19.7
33
43.8
Operating expenses
10.3
12.3
25.2
36.9
124
315
231
Operating income
-10.3
-12.3
-25.2
-36.9
-110
-306
-224
Interest expense
0.05
0.02
Other non-operating income
-5.58
0.49
0.01
Income tax
0
0
0
0
0
0
0
Net income
-10.4
-17.8
-24.7
-36.9
-107
-293
-212
EBITDA
-9.73
-11.5
-24.4
-36.5
-109
-304
-222
EPS, basic
-9.55
-5.26
-2.14
-3.09
-5.38
-5.00
-2.43
EPS, diluted
-9.55
-5.26
-2.14
-3.09
-5.38
-5.00
-2.43
Shares, basic (weighted)
1.09
3.39
11.5
12.1
19.8
58.6
87.4
Shares, diluted (weighted)
1.09
3.39
11.5
12.1
19.8
58.6
87.4
Balance sheet
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
2.54
39.8
49.2
20.3
98.7
143
653
Short-term investments
39.5
74
0
Other current assets
3.13
7.41
2.33
6.56
4.04
7.3
Total current assets
3.12
42.9
56.6
22.6
145
221
661
Property, plant and equipment
1.7
1.53
0.86
0.68
2.07
10.1
14.6
Lease right-of-use assets
0.28
1.56
4.28
2.98
Other non-current assets
0.14
0.1
4.41
4.59
Total assets
5.06
44.5
57.9
24
149
240
683
Accounts payable
0.55
1.19
3.08
2.4
3.31
14.2
3.34
Accrued liabilities
0.67
1.37
2.84
1.87
2.73
5.86
11.5
Deferred revenue
10.5
6.94
0
Short-term debt
0.37
Total current liabilities
1.67
3.04
9.73
7.33
21.8
54.3
45
Long-term debt
0.13
Lease liabilities
1.34
4.77
3.86
Other non-current liabilities
0.01
0.06
1.34
Total liabilities
1.8
3.18
9.74
7.39
28.7
59.1
48.8
Total debt
0.5
Paid-in capital
0.93
95.7
127
133
343
697
1,362
Retained earnings
-36.6
-54.4
-79.1
-116
-223
-516
-728
Other comprehensive income
0.02
0.06
0
Shareholders' equity
-35.6
41.3
48.2
16.7
120
181
634
Total equity
-35.6
41.3
48.2
16.7
120
181
634
Total liabilities and equity
5.06
44.5
57.9
24
149
240
683
Shares outstanding
1.1
10.6
12.1
12.1
43.3
64.5
113
Cash flow statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-10.4
-17.8
-24.7
-36.9
-107
-293
-212
Depreciation and amortization
0.62
0.76
0.76
0.42
0.46
1.57
2.47
Stock-based compensation
0.01
0.62
3.45
5.33
6.22
15.7
25.7
Change in payables
0.08
0.5
1.78
-0.68
-0.61
9.53
-9.16
Cash from operations
-9.6
-12.1
-18.2
-28.7
-7.57
-111
-191
Capital expenditures
-0.23
-0.59
-0.08
-0.25
-0.83
-7.17
-9.69
Purchases of investments
-38.9
-187
-123
Sales and maturities of investments
155
200
Cash from investing
-0.23
-0.59
-0.08
-0.25
-30.5
-85.1
60.8
Debt issued
0.5
Stock issued
0.01
44.9
1.34
0.03
0.03
20
45.9
Cash from financing
10.8
49.9
27.8
0.03
116
241
640
Net change in cash
0.94
37.2
9.46
-28.9
78.4
44.7
510
Free cash flow
-9.83
-12.7
-18.3
-28.9
-8.4
-118
-201
Interest paid
0.11
0.03
0.01
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $21.41 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-48.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-45.0%
Net income / average total assets.
Return on invested capital (ROIC)
-69.5%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-23.2%
Revenue vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
250.1%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
236.5%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
72.7%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
184.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
205.1%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
72.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
49.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
93.1%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
91.5%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
15.1x
Current assets / current liabilities.
Quick ratio
14.6x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
14.6x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.00
Revenue / diluted weighted shares.
FCF per share
-$1.93
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.84
Cash from operations / diluted weighted shares.
Book value per share
$4.63
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
4.63x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
4.63x
Market cap / tangible book value, when positive.
FCF yield
-9.0%
Free cash flow / market cap.
Earnings yield
-10.5%
Net income / market cap (the inverse of P/E).
What was Immunome Inc.'s revenue in fiscal 2025?
Immunome Inc. reported revenue of $6.9M for fiscal 2025, 23.2% lower than the year before.
Was Immunome Inc. profitable in fiscal 2025?
No. It reported a net loss of $212.4M.
How much free cash flow did Immunome Inc. generate in fiscal 2025?
Cash from operations of $190.9M minus capital expenditures of $9.7M left free cash flow of -$200.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.